SporeGen

SporeGen receives GRAS Notice No. GRN 000905 from the FDA for its probiotic SG188

  • June 10, 2020
  • SporeGen

SporeGen Ltd. is proud to announce that the FDA has issued a GRAS (Generally Recognized As Safe) Notice No. GRN 000905 for its probiotic strain Bacillus subtilis SG188TM (DSM 32444) under its intended conditions of use.

Intended for use as an ingredient in conventional foods includes as an ingredient in beverages, such as milk drinks, protein high energy sports drinks, hot beverages and juices; and dry and shelf-stable products such as cereals, cookies, gums and confectionary at a maximum of 109 spores per serving. Bacillus subtilis SG188TM spore is manufactured by fermentation of a pure culture under controlled conditions.

"SG188TM is a novel human isolate of B. subtilis that carries activity against the gut pathogen Helicobacter pylori. The strain also has utility for preventing respiratory infections. We are looking forward to seeing this unique strain enter the market” said Dr Simon M. Cutting, CEO of SporeGen. SporeGen is ready to license out the Bacillus subtilis SG188TM to potential food ingredient manufacturers and food producers.